CEL-SCI reports Q3 EPS ($1.36) vs. ($4.18) last year

“Commercial and regulatory momentum for Multikine is accelerating due to three driving factors-our partnership negotiations in Saudi Arabia, the increasing interest in CEL-SCI (CVM) from investors in the Middle East, and continued recognition in the global scientific and regulatory community that PD-L1 is a valuable predictive marker for head and neck cancer,” stated CEL-SCI CEO, Geert Kersten. “We are particularly encouraged about the potential for Multikine to become commercially available in Saudi Arabia in 2025. Should this happen, we believe it could support our regulatory and commercial efforts worldwide.”